Isatuximab
Isatuximab (pale blue) binding CD38 (purple). PDB: 4CMH | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD38 |
| Clinical data | |
| Trade names | Sarclisa |
| Other names | SAR-650984, isatuximab-irfc |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620023 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6456H9932N1700O2026S44 |
| Molar mass | 145190.99 g·mol−1 |
Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma.[6][4]
The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhoea and bronchitis (inflammation of the airways in the lungs).[4]
Isatuximab is an anti-CD38 mAb intended to treat relapsed or refractory multiple myeloma.[7] It entered in Phase II trials for multiple myeloma[8] and T-cell leukemia in 2015.[9]
- ^ a b "Sarclisa Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 14 May 2020. Archived from the original on 10 October 2021. Retrieved 16 August 2020.
- ^ "AusPAR: Isatuximab". Therapeutic Goods Administration (TGA). 27 May 2022. Archived from the original on 27 May 2022. Retrieved 12 June 2022.
- ^ "Summary Basis of Decision (SBD) for Sarclisa". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
- ^ a b c Cite error: The named reference
Sarclisa EPARwas invoked but never defined (see the help page). - ^ "Sarclisa Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ Cite error: The named reference
Sarclisa FDA labelwas invoked but never defined (see the help page). - ^ "ImmunoGen, Inc. Announces Data Presentations at Upcoming 57th ASH Annual Meeting and Exposition" (Press release). December 2015. Archived from the original on 19 October 2021. Retrieved 8 December 2015.
- ^ Martin T (2015). "A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma". Blood. 126 (23): 509. doi:10.1182/blood.V126.23.509.509.
- ^ "Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia". ClinicalTrials.gov. 8 January 2020. Archived from the original on 19 September 2020. Retrieved 4 March 2020.